As America prepares to head into another pandemic ahead of the critical November elections, the pharmaceutical industry is anticipating major profit surges.
Democrat President Joe Biden’s administration is now preparing to deploy mRNA vaccines for bird flu before voters head to the polls, according to a report from the Financial Times.
The report notes that the Biden admin is preparing to “bankroll a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine.”
H5N1 bird flu is spreading across the country as the November presidential elections draw near.
It comes as several prominent experts have already warned about dangerous biolabs experimenting with H5N1 gain-of-function.
It seems that it’s not all bad news for everyone, however.
Over the past several months, shares for mRNA vaccine makers have been ramping higher on bird flu headlines.
Sources familiar with the talks between Moderna and the government’s Biomedical Advanced Research and Development Authority (BARDA) reportedly told FT that Biden is planning to allocate taxpayer funds to the pharma company as early as this month.
“It is expected to total several tens of millions of dollars, and could be accompanied by a commitment to procure doses if the phase-three trials are successful,” they said.
Moderna has previously said it was trialing H5N1 flu vaccines.
The company revealed that the trials for mRNA bird flu vaccines started last summer, with interim data expected soon.
“Moderna is currently testing an H5N1 vaccine, from the 2.3.4.4b subset of viruses, in people,” Stat News reported.
“That trial began last summer.
“But the trial’s listing in the Clinicaltrials.gov database is cagey about the dosages Moderna is testing, calling them simply dose number 1, 2, and 3.”
As of last week, Biden’s Department of Agriculture had detected 67 dairy cow herds with H5N1 infections in nine states:
- Texas
- Kansas
- New Mexico
- Michigan
- Idaho
- North Carolina
- South Dakota
- Ohio
- Colorado.
The ongoing outbreak is linked to dairy cattle, placing America’s food supply at risk.
Only two H5N1 cases have been detected among humans.
The first was in April, with a Texas dairy worker, and the second was from a Michigan dairy farm last week.
Both had mild infections and have since recovered.
FT also said the federal government is in talks with Pfizer about an mRNA vaccine targeting H5N1.
If human-to-human cases surge, the Biden admin is expected to up the ante regarding the outbreak.
Just as we saw with Covid, the plan to deal with any future or potential “pandemic” will be to draft in Moderna and Pfizer to rapidly deploy their highly profitable and experimental injections.
Whether the Biden admin will move to force vaccine compliance so close to the election, remains to be seen, however.
Meanwhile, the Biden admin’s close relationship with the pharmaceutical industry appears to be working out very well for Moderna.
On Monday, Moderna announced that Biden’s Food and Drug Administration (FDA) now has officially approved another of its mRNA injections.
In an announcement, the company confirmed that “the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.”
The report said, “The approval was granted under a breakthrough therapy designation.”
https://slaynews.com/news/moderna-shares-surge-biden-prepares-deploy-bird-flu-mrna-vaccines-before-election/
No comments:
Post a Comment